A5009932128- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Platelet Disorders and Treatments
- Acute Myocardial Infarction Research
- Blood groups and transfusion
- Blood Coagulation and Thrombosis Mechanisms
- Diagnosis and Treatment of Venous Diseases
- Central Venous Catheters and Hemodialysis
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Complement system in diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Renal Diseases and Glomerulopathies
- Ultrasound in Clinical Applications
- Acute Ischemic Stroke Management
- Multiple Myeloma Research and Treatments
- COVID-19 Clinical Research Studies
- Cardiac, Anesthesia and Surgical Outcomes
- SARS-CoV-2 and COVID-19 Research
- Chronic Lymphocytic Leukemia Research
- Long-Term Effects of COVID-19
- Lymphoma Diagnosis and Treatment
- Maternal and fetal healthcare
- Infection Control in Healthcare
North Shore Hospital
2012-2024
Waitemata District Health Board
2013-2024
University of Auckland
2020-2022
Auckland City Hospital
2019
Monash Medical Centre
2010-2011
Monash Health
2010
Christchurch Hospital
2008
Canterbury Health Laboratories
2008
Introduction Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease and, globally, more than an estimated 10 million people have it yearly. It a chronic recurrent disease. The symptoms of VTE are non-specific diagnosis should actively be sought once considered. mainstay treatment anticoagulation, with few patients requiring additional intervention. A working group experts in area recently completed...
The aim of this study was to prospectively evaluate the use intraluminal ethanol for prevention catheter-associated bloodstream infection (CABSI) in immunosuppressed haematology patients. Patients receiving chemotherapy haematological malignancy or haematopoietic cell transplantation were randomized a double-blinded manner receive either 70% ethanol/water heparinized saline locks on daily basis throughout prophylactic treatment period. primary endpoint an episode CABSI (defined as...
BACKGROUND: Optimal thromboprophylaxis for hospitalized patients with coronavirus disease 2019 (Covid-19) is uncertain. METHODS: In an open-label, adaptive platform trial, we randomly assigned adults Covid-19 to low-dose low-molecular-weight heparin or intermediate-dose plus aspirin. response external evidence, the aspirin intervention was discontinued and a therapeutic-dose arm added. The primary end point death requirement new organ support by day 28, analyzed Bayesian logistic model....
Pulmonary embolism is one of the leading causes mortality in pregnancy Western world. No clinical prediction models have been validated pregnancy. As a result, any pregnant woman presenting with signs possibly consistent pulmonary investigated radiologically. This study investigates whether using for should be pursued future prospective trials. The aim this was to retrospectively evaluate Wells model and ventilation-perfusion scanning A retrospective performed on consecutive women who...
Symptomatic venous thromboembolism (VTE) complicates approximately 4% of major orthopaedic surgical procedures performed without thromboprophylaxis. Randomised clinical trials demonstrate primary thromboprophylaxis reduces VTE rates to <1%, with low clinically important bleeding, using molecular weight heparin (LMWH), oral FXa inhibitors or thrombin inhibitors. We reviewed the in patients undergoing hip/knee joint surgery at Waitemata District Health Board (WDHB).Cases within 90 days were...
It is unknown whether filling defects in subsegmental arteries on multidetector computed tomography pulmonary angiography correlate with clinically relevant embolism (PE) angiography. Current guidelines do not differentiate between PE segmental and vessels, many patients receive at least 3 months anticoagulation. The strategy employed North Shore Hospital haemodynamically stable single to perform bilateral lower leg compression ultrasound (CUS). Anticoagulation withheld if CUS negative; a...
Introduction The absence of high quality evidence for basic clinical dilemmas in immune thrombocytopenic purpura (ITP) underlines the need contemporary guidelines relevant to local treatment context. ITP is diagnosed by exclusions, with a hallmark laboratory finding isolated thrombocytopenia. Main recommendations Bleeding, family and medication histories review historical investigations are required gauge bleeding risk possible hereditary syndromes. Beyond platelet count, decision treat...
The PLASMIC score is a convenient tool for predicting ADAMTS13 activity of <10%. Lactate dehydrogenase (LDH) widely used as marker haemolysis in thrombotic thrombocytopenic purpura (TTP) monitoring, and could be replacement lysis. We aimed to validate the multi-centre Asia Pacific region, explore whether LDH lysis.Records patients with microangiopathy (TMA) were reviewed. Patients' levels obtained, along clinical/laboratory findings relevant score. Both scores PLASMIC-LDH scores, which...
Here, we present a series of illustrated capsules from the State Art (SOA) speakers at 2024 International Society on Thrombosis and Haemostasis Congress in Bangkok, Thailand. This year's marks first time that has held its flagship scientific meeting Southeast Asia is to be organized by an international Planning Committee. The Bangkok program will feature innovative science clinical updates around world, reflecting diversity multidisciplinary growth our field. In these SOA capsules, you find...
It is standard of care to treat proximal vein deep thrombosis (DVT) for a minimum 3 months. Conversely, management isolated distal DVT (IDDVT) controversial, with options including observation and repeat ultrasound scan within 1 week detect anticoagulate those propagation, or anticoagulation periods up months.The aim was assess the rates propagation venous thromboembolism (VTE) recurrence months diagnosis IDDVT, examine how duration treatment might influence this.Study patients were...
BackgroundImmune thrombocytopenia (ITP) has been reported following COVID-19 vaccination. After index case fatalities, there was concern among patients both with and without a prior history of ITP in Australia.ObjectivesTo describe treatment outcomes after vaccination compare relapsed vs historical pre-COVID-19 cohorts.MethodsWe collected cases Australia within 6 weeks receiving any as part primary (up to October 17, 2021). Second, we reviewed platelet charts cohort determine whether...
BackgroundRestoring hemostasis in patients on oral anticoagulants presenting with major hemorrhage (MH) or before surgical intervention has changed, the replacement of vitamin K antagonist (VKA) direct (DOACs).ObjectivesTo observe difference urgent hemostatic management between VKA and those DOACs.MethodsA multicenter observational study evaluated variation laboratory testing, management, mortality, hospital length stay (LOS) DOACs MH restoration.ResultsOf 1194 analyzed, 783 had (61% VKA)...
Abstract Background The recommended dose of idarucizumab, the specific reversal agent for dabigatran etexilate, is 5 g. However, published data showed biochemical after an initial 2.5 g dose. Objectives This study aims to retrospectively compare clinical effectiveness and doses idarucizumab used in three hospitals Auckland, New Zealand. Methods All patients receiving between April 1, 2016 December 31, 2018 were included. primary outcome was likelihood a second during same admission....
Objective: To measure the safety and acceptability of providing written advice (WA) for selected patients referred to a haematology service, as an alternative inpatient or outpatient assessment. Design, setting participants: Review initial management subsequent course newly tertiary referral hospital in Christchurch, New Zealand, between 16 October 2003 8 June 2006. Structured questionnaires were sent all referring doctors recently managed with WA. Main outcome measures: Numbers diagnoses...